What is the difference between ACE-031 and Myostatin Propeptide?

ACE-031: Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously Myostatin Propeptide: Endogenous N-terminal fragment of myostatin precursor; binds and neutralizes mature myostatin (GDF-8); naturally produced to regulate the extent of muscle inhibition

Is ACE-031 FDA approved?

ACE-031 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Myostatin Propeptide FDA approved?

Myostatin Propeptide is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ACE-031 administered in research settings?

In research settings, ACE-031 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Myostatin Propeptide administered in research settings?

In research settings, Myostatin Propeptide is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ACE-031 vs Myostatin Propeptide

Peptide Comparison

ACE-031 vs Myostatin Propeptide

Name: ACE-031 vs Myostatin Propeptide — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Muscle & Myostatin peptides.

ACE-031

ACVR2B-Fc

PerformanceInvestigationalResearch Only

Half-life: ~14 days

3 providers listed

Full ACE-031 profile →

Myostatin Propeptide

GDF-8 propeptide

PerformanceNot EvaluatedResearch Only

Half-life: Unknown

1 providers listed

Full Myostatin Propeptide profile →

Bottom line

ACE-031 carries stronger published evidence (RCT, 1 key studies) than Myostatin Propeptide (Animal, 2); both are research compounds.

Quick Verdict

ACE-031

Evidence

Emerging Clinical

Half-life

~14 days

Myostatin Propeptide

Evidence

Preclinical

Half-life

Unknown

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ACE-031
Further along in FDA review	ACE-031
More provider options (3 vs 1)	ACE-031

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ACE-031

Myostatin Propeptide

Mechanism Family

Muscle & Myostatin

Half-life

~14 days

Unknown

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

subcutaneous, intramuscular

Availability

Research Only

Providers

3 listed

1 listed

Avail. Notes

Activin receptor IIB-Fc fusion (ACVR2B decoy) by Acceleron Pharma. Phase 2 for Duchenne MD halted 2013 due to AEs (epistaxis, telangiectasia). Development discontinued. Previously held IND.

N-terminal propeptide of myostatin that inhibits myostatin signalling. No FDA approval, no NDA or IND. Research tool compound. Not on any FDA list. No active clinical development program.

Research Evidence

ACE-031

Emerging ClinicalRCT · 1 key study · most recent 2017

Myostatin Propeptide

PreclinicalAnimal · 2 key studies · dated evidence base — most recent 2004

Research Citations

ACE-031

RCT2017 · Muscle & Nerve

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a rando…

Myostatin Propeptide

Animal2004 · Proceedings of the National Academy of Sciences

Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases

Animal2001 · Proceedings of the National Academy of Sciences

Regulation of myostatin activity and muscle growth

About ACE-031

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

Research Areas

myostatin/activin inhibitionmuscle mass increasebone density improvement

About Myostatin Propeptide

Endogenous N-terminal fragment of myostatin precursor; binds and neutralizes mature myostatin (GDF-8); naturally produced to regulate the extent of muscle inhibition

Research Areas

myostatin inhibitionmuscle hypertrophystrength gainlean mass increase

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ACE-031

Reported (Unverified — Pending Clinical Review)

cardiovascular diseasetelangiectasia riskbleeding disorderspregnancy

No established clinical contraindications

Myostatin Propeptide

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Price (per mg)

ACE-031

$138.95/mg

$76.85 – $160.00 range

9 vendors

View price index →Find providers →

Myostatin Propeptide

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

ACE-031

3 listed

Browse directory →

Providers offering

Myostatin Propeptide

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Muscle & Myostatin Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 20, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ACE-031 vs Myostatin Propeptide — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/ace-031/myostatin-propeptide

https://peptidebase.io/peptides/compare/ace-031/myostatin-propeptide Methodology License Download JSON Download CSV